AJ17

AJ17 is a small molecule inhibitor of receptor tyrosine kinases (RTKs) currently in preclinical development. It is being investigated for its potential to enhance the therapeutic efficacy of agonist CD40 antibodies (αCD40) while simultaneously mitigating their associated toxicities, such as cytokine release syndrome (CRS) and hepatotoxicity (indicated by elevated ALT and AST levels). In murine models of melanoma and breast cancer, AJ17 has demonstrated the ability to attenuate αCD40-induced PD-L1 expression and increase the population of CD8+ T cells within the tumor microenvironment. The compound was developed by researchers at the Indian Institute of Technology (IIT) Delhi and IIT Kanpur.